Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
Victoria Snowdon(Centre for Inflammation Research), Jonathan Fallowfield(MRC Centre for Regenerative Medicine)
Cited by 64